← All trials
NCT05338450
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 30, 2022
- Primary completion
- May 31, 2024
- Completion date
- Nov 30, 2026
- First posted
- Apr 21, 2022
- Last posted
- Sep 23, 2022
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Free University of AmsterdamLead sponsor
- Free University of AmsterdamOverall official - principal investigator
- Free University of AmsterdamReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.